Claims
- 1. A composition of matter comprising a spacer and at least one gp120-binding peptide of from 17 to 50 amino acids conjugated to said spacer, wherein said peptide comprises amino acids 41-57 of CD4, wherein said composition reduces HIV binding to human cells in the presence of antibodies from an individual infected with HIV.
- 2. The composition of claim 1, wherein the gp120-binding peptide structure includes amino acids 41-84 of CD4.
- 3. The composition of claim 1, wherein the spacer comprises a serum soluble protein.
- 4. The composition of claim 3, wherein the protein spacer comprises OVA, BSA, HSA, poly-gly, or poly-ala.
- 5. The composition of claim 1, wherein the spacer comprises an N-hydroxysuccinimide ester.
- 6. The composition of claim 1, wherein the gp120-binding peptide includes from two to ten additional amino acids positioned at its carboxy terminus.
- 7. The composition of claim 1, wherein the gp120-binding peptide includes a carboxy terminal cysteine residue.
- 8. The composition of claim 3 or 5, wherein the gp120-binding peptide is conjugated to the spacer through a linker which includes a disulphide bond.
- 9. A pharmaceutical composition comprising a composition in accordance with claim 1, in combination with a pharmaceutically acceptable diluent.
- 10. A method for reducing the binding of HIV to human cells in the presence of antibodies of an individual infected with HIV, the method comprising:
- (a) preparing a composition of matter comprising a spacer and at least one gp120 -binding peptide of from 17 to 50 amino acids conjugated to said spacer, wherein said peptide comprises amino acids 41-57 of CD4; and
- (b) contacting the human cells with said composition of matter in an amount effective to reduce the binding of HIV to said cells in the presence of such antibodies.
- 11. The method of claim 10, wherein the spacer comprises a serum soluble protein.
- 12. The method of claim 11, wherein the protein spacer comprises OVA, BSA, HSA, poly-gly, or poly-ala.
- 13. The method of claim 10, wherein the spacer comprises an N-hydroxysuccinimide ester.
- 14. The method of claim 10 or 11, wherein the gp120-binding peptide is not conjugated to a toxin molecule.
- 15. The method of claim 10, wherein step (b) comprises administering the gp120-binding peptide to an HIV infected individual.
- 16. The method of claim 10, wherein the gp120-binding peptide is one having the ability to reduce binding of HIV to human cells in the presence of antibodies to the CD4 protein.
- 17. The method of claim 10, wherein the gp120-binding peptide structure includes amino acids 41-84 of CD4.
Parent Case Info
This application is a continuation, of application Ser. No. 07/792,212, filed Nov. 13, 1991, now abandoned, which is a continuation-in-part of U.S. Ser. No. 07/519,240, filed May 3, 1990, now abandoned, which is a continuation of U.S. Ser. No. 07/407,479, filed Sep. 14, 1989, now abandoned.
Government Interests
The government may own certain rights in the present invention pursuant to NIH grants CA-28149, CA-41081, CA-09082, and RR-00890.
US Referenced Citations (3)
Number |
Name |
Date |
Kind |
4935465 |
Garman et al. |
Jun 1990 |
|
5116944 |
Sivam et al. |
May 1992 |
|
5206353 |
Berger et al. |
Apr 1993 |
|
Foreign Referenced Citations (3)
Number |
Date |
Country |
0 314 317 A1 |
May 1989 |
EPX |
WO8702987 |
May 1987 |
WOX |
WO8902922 |
Apr 1989 |
WOX |
Non-Patent Literature Citations (4)
Entry |
Schniffman et al. (1988) J. Immunol. 141, 4181-4186. |
Ghetie et al. (1991) Proc. Natl. Acad. Sci. 88, 5690-5693. |
"HIV-Infected Cells Are Killed by rCD4-Ricin A Chain", Science, Nov. 25, 1988, vol. 242, pp. 1166-1168. |
"Studies are Exploring Potential of Soluble CD4 Therapy for HIV", Exchange, published by NIAID, May/Jun., 1989, pp. 5-9. |
Continuations (2)
|
Number |
Date |
Country |
Parent |
792212 |
Nov 1991 |
|
Parent |
407479 |
Sep 1989 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
519240 |
May 1990 |
|